XMAG - ETF AI Analysis

Top Page

Defiance Large Cap ex-Mag 7 ETF (XMAG)

Rating:71Outperform

Price Target:―

The ETF XMAG's overall rating reflects a balanced mix of strong performers and some holdings with tempered outlooks. Top contributors like Broadcom and Johnson & Johnson drive the fund's positive rating, thanks to their strong financial performance and strategic focus on high-growth areas such as AI and healthcare. However, weaker momentum and valuation concerns in holdings like Netflix and Mastercard slightly weigh on the overall score. Investors should note the potential risk of sector concentration in technology and healthcare, which could impact performance during market downturns in these industries.

Positive Factors

Strong Top Holdings

Several key positions, such as Broadcom and Oracle, have delivered strong year-to-date performance, supporting the ETF's overall returns.

Sector Diversification

The ETF is spread across multiple sectors, including Technology, Financials, and Health Care, reducing reliance on any single industry.

Moderate Expense Ratio

The fund's expense ratio of 0.35% is relatively low, making it cost-effective compared to many actively managed funds.

Negative Factors

Overwhelming U.S. Exposure

With over 98% of assets in U.S. companies, the ETF lacks meaningful international diversification.

Underperforming Holdings

Some top holdings, such as Eli Lilly and Exxon Mobil, have shown weaker year-to-date performance, which could drag on returns.

Small Asset Base

The ETF's relatively low assets under management may lead to less liquidity and higher trading costs for investors.

XMAG vs. SPDR S&P 500 ETF (SPY)

AUM74.80M

RegionNorth America

Expense Ratio0.35%

Beta0.88

IssuerDefiance

Inception DateOct 21, 2024

Dividend YieldN/A

Asset ClassEquity

Index TrackedBITA US 500 ex-Magnificent 7 Index - Benchmark TR Gross

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume71,618

30 Day Avg. Volume46,375

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

25.69

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering494

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

XMAG Summary

The Defiance Large Cap ex-Mag 7 ETF (XMAG) is an investment fund that focuses on large-cap companies while excluding the seven biggest tech giants, often called the 'Mag 7.' This ETF includes well-known companies like Broadcom and JPMorgan Chase, offering exposure to diverse sectors such as financials, healthcare, and consumer goods. Investors might consider XMAG for balanced growth and diversification without heavy reliance on mega-cap tech stocks. However, a key risk is that the fund’s performance can still fluctuate with the broader market, as it includes companies from various industries.

How much will it cost me?The expense ratio for the Defiance Large Cap ex-Mag 7 ETF (XMAG) is 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed to exclude the 'Mag 7' tech giants, requiring more oversight and strategy. It’s designed for investors seeking a unique approach to large-cap stocks.

What would affect this ETF?XMAG's focus on excluding the 'Mag 7' tech giants could benefit from a shift in investor sentiment towards diversification and reduced reliance on mega-cap tech stocks. Positive drivers include potential growth in sectors like financials and healthcare, which are significant holdings, and stability from its broad exposure to U.S. large-cap companies. However, negative factors such as rising interest rates could pressure financial stocks, and economic slowdowns might impact consumer-focused sectors like Consumer Defensive and Consumer Cyclical.

XMAG Top 10 Holdings

The XMAG ETF offers a refreshing take on large-cap investing by sidestepping the tech-heavy 'Magnificent 7,' but technology still plays a significant role, led by Broadcom, which has shown steady gains this year despite valuation concerns. Healthcare giant Eli Lilly is a standout performer, riding strong revenue growth and a promising drug pipeline. On the financial side, JPMorgan Chase is steady but faces headwinds from rising credit costs. Meanwhile, Visa and Mastercard are lagging, weighed down by bearish momentum and valuation worries. With its U.S.-focused, sector-diverse approach, XMAG balances growth potential with reduced tech volatility.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
AVGO	Broadcom	4.86%	$3.63M	$1.92T	125.42%	76 Outperform
LLY	Eli Lilly & Co	2.15%	$1.61M	$928.57B	24.82%	72 Outperform
JPM	JPMorgan Chase	2.13%	$1.59M	$818.07B	27.34%	72 Outperform
BRK.B	Berkshire Hathaway B	1.69%	$1.26M	$1.06T	6.29%	66 Neutral
	―	1.63%	$1.22M	―	―	―
V	Visa	1.44%	$1.07M	$624.35B	3.80%	70 Outperform
XOM	Exxon Mobil	1.31%	$981.00K	$498.68B	6.81%	74 Outperform
WMT	Walmart	1.30%	$968.34K	$917.05B	19.19%	78 Outperform
JNJ	Johnson & Johnson	1.25%	$931.61K	$481.76B	40.85%	78 Outperform
MA	Mastercard	1.15%	$857.93K	$482.72B	0.82%	75 Outperform

XMAG Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

22.28

Positive

100DMA

21.96

Positive

200DMA

21.00

Positive

Market Momentum

MACD

0.12

Negative

RSI

60.31

Neutral

STOCH

66.17

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XMAG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 22.29, equal to the 50-day MA of 22.28, and equal to the 200-day MA of 21.00, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 60.31 is Neutral, neither overbought nor oversold. The STOCH value of 66.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XMAG.

XMAG Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
XMAG	―	―	$74.80M	0.35%	―
ONEO	―	―	$97.34M	0.20%	―
UPSD	―	―	$96.61M	0.79%	―
LVDS	―	―	$96.44M	0.30%	―
BCUS	―	―	$94.95M	0.70%	―
HUSV	―	―	$91.25M	0.70%	―

Performance Comparison

XMAG

Defiance Large Cap ex-Mag 7 ETF

22.72

2.52

12.48%

ONEO

SPDR Russell 1000 Momentum Focus ETF

―

UPSD

Aptus Large Cap Upside ETF

―

LVDS

JPMorgan Fundamental Data Science Large Value ETF

―

BCUS

Bancreek U.S. Large Cap ETF

―

HUSV

First Trust Horizon Managed Volatility Domestic ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents